De-ESCALaTE HPV: Determination of Epidermal growth factor receptor-inhibitor (cetuximab) versus Standard Chemotherapy (cisplatin) early And Late Toxicity Events in Human Papillomavirus-positive oropharyngeal squamous cell carcinoma

Fulton-Lieuw, Tessa

doi:10.1186/isrctn33522080

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two ongoing phase III studies (RTOG 1016 [60] and DE-ESCALATE [61])are comparing cetuximab combined with IMRT with P-RT in HPV-associated LA oral squamous cell carcinoma. In the latter, only low-risk patients with HPV-positive oral squamous cell carcinoma will be included.…”

Section: Hpv Statusmentioning

confidence: 99%

State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013

Denaro¹,

Russi

Adamo

et al. 2014

Oncology

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cause of cancer death worldwide. Its treatment is complex and evolving. In general, early-stage disease may be managed with single-modality treatment while an advanced stage (about 60% of clinical presentation) needs a multidisciplinary approach. In this setting concurrent chemoradiation has been associated with improvement in locoregional control and organ preservation, but at the cost of significant acute and chronic toxicity. Molecular target therapies specially directed to epidermal growth factor receptor (EGFR) might improve the outcomes and reduce toxicities. In recurrent-metastatic (R/M) HNSCC, cetuximab, a monoclonal antibody against EGFR, plus platinum-based chemotherapy (CT) allow an overall survival (OS) of about 10 months. However, the prognosis for R/M-HNSCC remains dismal and additional efforts are needed. At the 2013 American Society of Clinical Oncology (ASCO) Meeting, data on induction CT, anti-EGFR inhibitors, innovative molecular targets and predictor factors were reported. Further results on target therapies were presented at the European Cancer Congress (ECC) 2013, where a large study also showed that hyperfractionated radiotherapy (RT) improve OS rates compared with standard RT. The aim of this review is to discuss current standards and emerging therapies by considering recent new updates.

show abstract

Section: Hpv Statusmentioning

confidence: 99%

State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013

Denaro¹,

Russi

Adamo

et al. 2014

Oncology

View full text Add to dashboard Cite

show abstract

“…29 Effect of treatment modality on swallowing As a surrogate marker of treatment-associated dysphagia, the requirement for either a nasogastric tube or PEG feeding after treatment was assessed. Therefore, we sought to establish whether components of the TNM system, or heavy smoking influenced the response of HPVpositive oropharyngeal SCC to differing treatment modalities.…”

Section: Differences In Tnm Staging Between Human Papillomavirus-negamentioning

confidence: 99%

Staging and treatment of oropharyngeal cancer in the human papillomavirus era

et al. 2014

View full text Add to dashboard Cite

Background Oropharyngeal squamous cell carcinoma (SCC) is staged using the TNM system. Human papillomavirus (HPV)‐positive tumors have improved prognosis, despite presenting at advanced stage. Optimal treatment and stratification of HPV‐positive patients are not clearly defined. Methods We retrospectively analyzed 266 patients with oropharyngeal SCC for mortality and feeding tube dependency related to TNM stage, HPV status, and treatment. Results TNM staging was prognostic in HPV‐negative patients (stage III/IV hazard ratio [HR], 2.00; p = .05; N+ HR, 2.19; p = .02). Only T classification was prognostic in HPV‐positive tumors (T3/T4 HR 3.31; p = .006). HPV‐positive tumors showed improved survival regardless of treatment. Patients receiving chemotherapy had a significantly increased risk of feeding tube dependency (odds ratio [OR], 1.72; p = .03). Conclusion These data suggest that the current TNM system has little prognostic value in HPV‐positive oropharyngeal SCC. Patients with HPV‐positive tumors show improved survival independent of treatment. The addition of chemotherapy increases the risk of feeding tube dependency and could potentially be avoided in T1/T2 HPV‐positive tumors without compromising survival. © 2014 Wiley Periodicals, Inc. Head Neck 37: 1002–1013, 2015

show abstract

“…Within the pivotal Radiation Therapy Oncology Group (RTOG) study by Ang et al [1], the 3 year overall survival for HPV-negative tumours treated with chemoradiation was 57.1% compared with 82.4% (P < 0.001) for HPV-positive tumours. Although there is interest in reducing the intensity of treatment in patients with HPV-positive OPSCC [2,3], HPV-negative OPSCC patients, and HPV-positive heavy smokers, warrant investigation of treatment intensification to improve survival.…”

Section: Introductionmentioning

confidence: 99%

Feasibility of Dose-escalated Hypofractionated Chemoradiation in Human Papilloma Virus-negative or Smoking-associated Oropharyngeal Cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

De-ESCALaTE HPV: Determination of Epidermal growth factor receptor-inhibitor (cetuximab) versus Standard Chemotherapy (cisplatin) early And Late Toxicity Events in Human Papillomavirus-positive oropharyngeal squamous cell carcinoma

Cited by 4 publications

References 0 publications

State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013

State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013

Staging and treatment of oropharyngeal cancer in the human papillomavirus era

Feasibility of Dose-escalated Hypofractionated Chemoradiation in Human Papilloma Virus-negative or Smoking-associated Oropharyngeal Cancer

Contact Info

Product

Resources

About